BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23975242)

  • 1. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
    Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
    Shang BY; Shang Y; Zhen YS; Chen SZ
    Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
    Ko JC; Tsai MS; Kuo YH; Chiu YF; Weng SH; Su YC; Lin YW
    Biochem Pharmacol; 2011 Mar; 81(5):680-90. PubMed ID: 21168393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H; Li L; Li XQ; Liu XJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
    Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
    Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioluminescence imaging evaluation of the inhibitory effect of lidamycin on lung metastasis of human fibrosarcoma in athymic mice].
    Zhang SH; Zhong GS; He HW; Cheng X; Zhen YS
    Yao Xue Xue Bao; 2011 Jan; 46(1):45-9. PubMed ID: 21465808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J; Ouyang ZG; Zhang SH; Zhen YS
    Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
    Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
    J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro.
    Liu F; Shang Y; Chen SZ
    Acta Pharmacol Sin; 2014 May; 35(5):645-52. PubMed ID: 24727941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
    Zheng MF; Shen SY; Huang WD
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1031-41. PubMed ID: 24043136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
    Fujimoto-Ouchi K; Tanaka Y; Tominaga T
    Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
    Xiao YS; Tang ZY; Fan J; Zhou J; Wu ZQ; Sun QM; Xue Q; Zhao Y; Liu YK; Ye SL
    J Cancer Res Clin Oncol; 2004 Sep; 130(9):546-50. PubMed ID: 15071737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
    Terranova-Barberio M; Roca MS; Zotti AI; Leone A; Bruzzese F; Vitagliano C; Scogliamiglio G; Russo D; D'Angelo G; Franco R; Budillon A; Di Gennaro E
    Oncotarget; 2016 Feb; 7(7):7715-31. PubMed ID: 26735339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
    Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
    Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
    Sawada N; Ishikawa T; Fukase Y; Nishida M; Yoshikubo T; Ishitsuka H
    Clin Cancer Res; 1998 Apr; 4(4):1013-9. PubMed ID: 9563897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model.
    de Souza CM; Araújo e Silva AC; de Jesus Ferraciolli C; Moreira GV; Campos LC; dos Reis DC; Lopes MT; Ferreira MA; Andrade SP; Cassali GD
    Biomed Pharmacother; 2014 Feb; 68(1):51-7. PubMed ID: 24054045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
    Hiraga T; Hata K; Ikeda F; Kitagaki J; Fujimoto-Ouchi K; Tanaka Y; Yoneda T
    Oncol Rep; 2005 Sep; 14(3):695-9. PubMed ID: 16077977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.